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Introduction: Circulating tumor cells (CTCs) are an independent prognostic factor for progression-free survival (PFS)
and overall survival (OS) in patients with metastatic breast cancer. Inflammatory breast cancer (IBC) is one of the
most aggressive forms of breast cancer. The prognostic value of a CTC count in newly diagnosed IBC has not been
established. The aim of this study was to assess the prognostic value of a baseline CTC count in patients with newly
diagnosed IBC.
Methods: This retrospective study included 147 patients with newly diagnosed IBC (77 with locally advanced and
70 with metastatic IBC) treated with neoadjuvant therapy or first-line chemotherapy during the period from January
2004 through December 2012 at The University of Texas MD Anderson Cancer Center. CTCs were detected and
enumerated by using the CellSearch system before patients were started with chemotherapy.
Results: The proportion of patients with ≥1 CTC was lower among patients with stage III than among patients with
metastatic IBC (54.5% versus 84.3%; P = 0.0002); the proportion of patients with ≥5 CTCs was also lower for stage III
than for metastatic IBC (19.5% versus 47.1%; P = 0.0004). Patients with fewer than five CTCs had significantly better
progression-free survival (PFS) (hazard ratio (HR) = 0.60; P = 0.02) and overall survival (HR = 0.59; P = 0.03) than patients
with five or more CTCs. Among patients with stage III IBC, there was a nonsignificant difference in PFS (HR = 0.66; 95%
confidence interval (CI), 0.31 to 1.39; P = 0.29) and OS (HR = 0.54; 95% CI, 0.24 to 1.26; P = 0.48) in patients with no
CTCs compared with patients with one or more CTCs. In multivariate analysis, CTC was prognostic for PFS and OS
independent of clinical stage.
Conclusions: CTCs can be detected in a large proportion of patients with newly diagnosed IBC and are a strong
predictor of worse prognosis in patients with newly diagnosed IBC.Introduction
Inflammatory breast cancer (IBC) is one of the most
aggressive forms of primary breast cancer, and the
incidence of IBC is increasing [1]. The prognosis of
patients with IBC remains poor: the 10-year disease-free
survival rate is only 20% to 25%, despite a multimodality
treatment approach [2-7]. These reports suggest that
current treatment modalities are inadequate and underscore
the need for better understanding of this disease.* Correspondence: jreuben@mdanderson.org
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unless otherwise stated.IBC is associated with special clinical and biological
features and a distinctive pattern of recurrence with
high incidence of visceral metastases (central nervous
system, lung, and liver) as first site of relapse [3-7]. It
is characterized by a high proliferation rate, frequent
hormone-receptor negativity, HER2 overexpression,
high grade, and increased tumor angiogenesis [7-11].
Studies of several molecular factors in IBC suggest
frequent epidermal growth factor receptor overexpression
and high expression of p53, MUC1, RhoC, E-cadherin,
and transcription factors associated with a stem cell
phenotype [12-17].
In patients with metastatic breast cancer, circulating
tumor cells (CTCs) are an independent predictor of
progression-free survival (PFS) and overall survivalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Patients’ flow.
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survival was observed among patients with fewer than
five CTCs per 7.5 ml of peripheral blood regardless
of histologic subtype, hormone receptor and HER2/neu
status, sites of first metastasis, or whether the patient had
recurrent or de novo metastatic disease [18-21]. The
prognostic value of a CTC count was found to be superior
to that of tumor burden as measured by Swenerton score
or by serum tumor markers, ascribing a peculiar biological
value to CTCs. These observations also raised the possibil-
ity that CTCs might represent a population of tumorigeniccancer cells with stem cell properties that might play an
important role in tumor dissemination [22,23].
Previously, we showed that among patients with
metastatic breast cancer (MBC) treated with first or
subsequent lines of chemotherapy, patients with meta-
static IBC had lower CTC counts than did patients
with non-inflammatory metastatic breast cancer (non-IBC)
[24]. We also showed, for patients with metastatic
IBC, that differences in OS between patients with
fewer than five CTCs and others with five or more
CTCs were not statistically significant; hence, the
Table 1 Patient characteristics and prevalence of circulating tumor cells at baseline (n = 147)
Stage III IBC Metastatic IBC
Characteristic N % ≥1 CTCa % ≥5 CTCa % N % ≥1 CTCa % ≥5 CTCa %
All patients 77 100.0 42 54.5 15 19.5 70 100.0 59 84.3 32 45.7
Histology
Infiltrative ductal carcinoma 74 96.1 40 54.1 15 20.3 66 94.3 55 83.3 31 47.0
Other histology 3 3.9 2 66.7 0 0.00 4 5.7 4 100.0 1 25.0
P value 1.00 0.61 0.61 0.62
ER/PR status
Positive for either 43 55.8 19 44.2 5 11.6 40 57.1 33 82.5 20 50.0
Negative for both 34 44.2 23 67.6 10 29.4 30 42.9 26 86.7 12 40.0
P value 0.06 0.08 0.74 0.47
HER-2/neu status
Overexpressed 26 33.8 17 65.4 7 26.9 19 27.1 13 68.4 9 47.4
Negative 51 66.2 25 49.0 8 15.7 51 72.9 46 90.2 23 45.1
P value 0.23 0.36 0.04 1.00
Grade
High grade 55 71.4 32 58.2 11 20.0 53 75.7 43 81.1 24 45.3
Intermediate/low grade 22 28.6 10 45.5 4 18.2 15 21.4 14 93.3 8 53.3
Unknown - - - - - - 2 2.9 2 - 0 -
P value 0.31 1.00 0.43 0.77
ER/PR and HER2/neu status
Triple receptor negative 19 24.7 12 63.2 5 26.3 19 27.1 17 89.5 7 36.8
Not-triple receptor negative 58 75.3 30 51.7 10 17.2 51 72.9 42 82.4 25 49.0
P value 0.44 0.50 0.71 0.43
Sites of metastases
Non-visceral - - - - - - 42 60.0 34 81.0 18 42.9
Visceral - - - - - - 28 40.0 25 89.3 14 50.0
P value 0.50 0.63
Bone metastasis
Present - - - - - - 39 55.7 32 82.1 19 48.7
Absent - - - - - - 31 44.3 27 87.1 13 41.9
P value 0.70 0.63
Number of metastases
1 - - - - - - 29 41.4 22 75.9 13 44.8
≥2 - - - - - - 41 58.6 37 90.2 19 46.3
P value 0.20 1.00
Statin use
No-statins 62 80.5 39 62.9 14 22.6 60 85.7 51 85.0 30 50.0
L-statinsb 7 9.1 1 14.3 1 14.3 5 7.1 5 100.0 1 20.0
H-statinsb 8 10.4 2 25.0 0 0.0 5 7.1 3 60.0 1 20.0
P value 0.01 0.30 0.20 0.21
Menopausal status
Premenopausal 27 35.1 19 70.4 9 33.3 25 35.7 21 84.0 13 52.0
Postmenopausal 50 64.9 23 46.0 6 12.0 45 64.3 38 84.4 19 42.2
P value 0.06 0.03 1.00 0.46
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Table 1 Patient characteristics and prevalence of circulating tumor cells at baseline (n = 147) (Continued)
Lymphovascular tumor emboli
Present 36 46.8 20 55.6 9 25.0 42 60.0 37 88.1 17 40.5
Absent 40 51.9 21 52.5 6 15.0 24 34.3 18 75.0 12 50.0
Unknown 1 1.3 1 - 0 - 4 5.7 4 - 3 -
P value 0.64 0.39 0.19 0.61
ER, estrogen receptor; PR, progesterone receptor.
aPer 7.5 ml of whole peripheral blood.
bLipophilic statins were classified as L-statins, and weakly lipophilic to hydrophilic statins were classified as H-statins.
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treated metastatic IBC is limited [24]. The prognostic
value of a CTC count in newly diagnosed IBC has
not been established.
In the present study, we investigated the prognostic
value of a baseline CTC count and the relation between
a baseline CTC count and primary tumor characteristics
in patients with newly diagnosed IBC. Recent data sug-
gest that statins might have anticancer effect in IBC, and
their use was associated with prolonged PFS in primary
IBC [25]. Therefore, we performed exploratory analysis
to evaluate the relation between exposure to statin before
diagnosis of IBC and CTC count.
Methods
Study patients
This retrospective study was conducted under Institutional
Review Board (IRB)-approved protocol DR10-0227 by
using the Clinic Station, the MD Anderson Cancer Center
(MDACC) electronic medical record database. Patients
were identified by using two databases; database of newly
diagnosed IBC patients treated in MD Anderson Cancer
Center between 1989 and 2011, as described in the
previous study [3], and the MDACC IBC database
with available data from 2007 to 2012 (Figure 1). A
population of consecutive stage III IBC and metastatic
IBC patients with CTCs measurement before starting
neoadjuvant or first-line treatment, was eligible. Only
treatment-naïve patients with newly diagnosed disease,
starting treatment with neoadjuvant or first-line chemo-
therapy, were included in this study. Patients underwent
systemic therapy, as appropriate for their malignancies,
irrespective of CTCs. Patients with concurrent malignancy
other than nonmelanoma skin cancer in the previous
5 years were excluded.
All patients underwent pretreatment diagnostic biopsy.
The diagnosis of IBC was based on clinical signs such as
diffuse erythema, peau d'orange, tenderness, induration,
and warmth [26,27]. The presence of dermal lymphatic
emboli in the diagnostic pathology report was not
mandatory for the pathological diagnosis of IBC.
Clinical stage at diagnosis of primary disease was
coded according to the criteria set forth in the sixthedition of the American Joint Committee on Cancer’s
AJCC Cancer Staging Manual [28].
In all patients, data regarding age, menopausal status,
tumor histologic subtype, hormone-receptor status,
HER2 amplification status, type and number of sites of
metastases, delivery of systemic therapy, and outcome
(progression, survival, pathological complete remission)
were recorded and compared with the presence and
number of CTCs. Because statins might have an antitumor
effect in IBC, we also recorded statin use before the
diagnosis of IBC [25]. Lipophilic statins (simvastatin,
fluvastatin, and lovastatin) were classified as L-statins,
and weakly lipophilic-to-hydrophilic statins (atorvastatin,
pravastatin, and rosuvastatin) were classified as H-statins,
as described previously [25].
The retrospective study was approved by the Institutional
Review Board of the University of Texas, MD Anderson
Cancer Center, and a waiver of consent form was granted.Detection of CTCs in peripheral blood
The CellSearch system (Veridex Corporation, Warren,
NJ, USA) was used to detect and enumerate CTCs in
7.5 ml of whole peripheral blood. Samples were subjected
to enrichment of epithelial cells with anti-EpCAM-coated
ferrous particles. CTCs were defined as nucleated cells
(DAPI+) expressing cytoplasmic cytokeratins 8, 18, or 19
and lacking surface expression of the common leukocyte
antigen (CD45) [18]. Specimens were stored at room
temperature and processed for detection of CTCs by using
CellSearch within 1 day of phlebotomy.Statistical analysis
Patient characteristics were tabulated. Baseline CTC
count was defined as the earliest CTC measurement
obtained before the start of a new line of therapy.
We dichotomized baseline CTC counts in two different
ways: as <1 or ≥1 and as <5 or ≥5. The cut-off at 1 CTC
was chosen because it has been investigated in other
settings, such as primary breast cancer, including locally
advanced breast cancer [29,30]. The cut-off at 5 CTCs was
established as prognostic for PFS and OS in patients with
metastatic breast cancer in a previous study [18].
Figure 2 Kaplan-Meier estimates of probabilities of progression-free survival, according to baseline circulating tumor cell count in
patients with newly diagnosed inflammatory breast cancer.
Mego et al. Breast Cancer Research  (2015) 17:2 Page 5 of 12In an exploratory analysis, we correlated baseline CTC
counts with PFS and OS. Median follow-up period was
calculated as a median observation time among all
patients and among those still alive at the time of
their last follow-up. PFS was calculated from the date
of baseline CTC enumeration to the date of progression
or death or the date of last adequate follow-up. OS was
calculated from the date of baseline CTC enumeration to
the date of death or last follow-up. PFS and OS were
estimated by using the Kaplan-Meier product-limit
method and compared between groups by using the
log-rank test. Univariate analyses were performed with
either χ2 or Fisher Exact test, as appropriate. A multivari-
ate Cox proportional hazards model for PFS and OS was
used to assess differences in outcome on the basis of
baseline CTC counts, hormone-receptor status (positive for
either or negative for both), HER-2 status (overexpressed or
negative), stage (stage III versus metastatic IBC), site of
metastasis (visceral versus non-visceral), and number of
metastatic sites. Visceral metastases were defined here as
lung, liver, adrenal gland, brain, kidney, pancreas, and/or
peritoneal involvement with or without ascites and/or
pleural effusions. Nonvisceral metastases were defined as
involvement of any of the following sites without visceral
metastases: breast, lymph nodes, chest wall, bone, skin,
and/or abdomen. Step-wise regression techniques wereused to build multivariate models by using a significance
level of 0.10 to remain in the model. Wilcoxon matched-
pairs signed-ranks test was used to compare baseline CTC
counts with CTC counts at the time of progression, and
Mann–Whitney U test was used to compare CTC counts
between patients with stage III IBC and metastatic
IBC. All statistical tests were two-sided, and P values <0.05
were considered statistically significant.
Results
Patient characteristics
A total of 147 patients with newly diagnosed IBC that
matched the study eligibility criteria was included in this
analysis. Of these 147 patients, 77 had locally advanced
(stage IIIB and IIIC) and 70 had metastatic IBC. Thirteen
patients (8.7%) with newly diagnosed metastatic IBC
(mIBC) in this analysis were also included in a previous
report [24]. The median age of the subjects was 54 years
(range, 23 to 82 years). One hundred forty patients (95.2%)
had invasive ductal carcinoma. Patients’ characteristics and
the prevalence of baseline CTCs are shown in Table 1.
Role of CTCs in IBC
Median baseline CTC count among the 147 patients
assessed for the presence of CTCs was 2 (range, 0 to 249)
per 7.5 ml of peripheral blood (PB). Among the 147
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CTC, whereas 48 patients (32.7%) had at least five CTCs.
The median CTC counts in patients with stage III
and mIBC were 1 (range, 0 to 179) and 3 (range, 0
to 249) (P < 0.0001), respectively. The proportion of
patients with one or more CTCs was lower in patients
with stage III than in patients with mIBC (54.5% versus
84.3%; P = 0.0002); the proportion of patients with five or
more CTCs was also lower for stage III than for mIBC
(19.5% versus 47.1%; P = 0.0004). The proportion of
patients with one or more and five or more CTCs was
higher in premenopausal than in postmenopausal women
in stage III IBC but not in mIBC patients (Table 1), and
there was a trend to detect CTCs more often in patients
with than in patients without lymphovascular tumor
emboli (74.4% versus 59.4%; P = 0.07).
At a median follow-up time of 26.3 months (range, 1.0
to 92.4 months), 81 patients (55.1%) had experienced
disease progression, and 66 patients (44.9%) had died.
Median follow-up of patients still alive was 35.6 (range,
8.2 to 92.4 months). Patients with fewer than five CTCs
had a significantly better PFS than patients with five or
more CTCs (median PFS, 26.4 versus 10.5 months;
hazard ratio [HR] = 0.60; 95% CI, 0.37 to 0.98; P = 0.02)
(Figure 2). Furthermore, patients with fewer than five
CTCs had a significantly better OS than patients with fiveFigure 3 Kaplan-Meier estimates of probabilities of overall survival, a
newly diagnosed inflammatory breast cancer.or more CTCs (median OS, 56.9 versus 32.7 months; HR
= 0.59; 95% CI, 0.35 to 1.00; P = 0.03) (Figure 3). Similarly,
with a cut-off of one CTC, patients with fewer than one
CTCs had a significantly better PFS (HR = 0.42; 95%
CI, 0.27 to0.66; P = 0.001) and OS (HR = 0.35; 95% CI,
0.21 to 0.58; P = 0.001) compared with patients with
one or more 1CTCs.
Tables 2 and 3 and Figures 4 and 5 summarize the
Kaplan-Meier PFS and OS estimates by CTC count
and patient tumor characteristics for stage III IBC
and metastatic IBC patients. CTC prognostic value
was observed only in metastatic IBC patients, with a
threshold of one CTC (Table 3). In multivariate analysis
baseline CTCs, HER2 status and stage of disease were
independent prognostic factors for PFS, whereas base-
line CTCs, hormone-receptor status, HER2 status,
and visceral metastases were independent prognostic
factors for OS (Table 4). Same results were obtained
by using a cut-off of one or more CTCs (data not
shown).
Relation of Statin and CTCs in IBC
We identified 25 patients (17%) that used statins before
the diagnosis of IBC (Table 1). Interestingly, an inverse
association was noted between the use of statins and the
presence of CTCs. The proportion of patients with ≥1ccording to baseline circulating tumor cells count in patients with
Table 2 Kaplan-Meier progression-free survival (PFS) and overall survival estimates stratified by CTC level and patient
and tumor characteristics in patients with newly diagnosed stage III inflammatory breast cancer
Progression-free survival Overall survival
Variable Hazard ratio Lower 95% CI Upper 95% CI P value Hazard ratio Lower 95% CI Upper 95% CI P value
All patients
<1 CTC versus ≥1 CTC 0.66 0.31 1.39 0.29 0.57 0.25 1.31 0.21
<5 CTC versus ≥5 CTC 0.69 0.26 1.78 0.39 0.72 0.26 2.00 0.48
ER/PR positive for either
<1 CTC versus ≥1 CTC 0.59 0.23 1.53 0.28 0.59 0.18 1.94 0.40
<5 CTC versus ≥5 CTC 0.33 0.06 1.70 0.04 0.33 0.05 2.18 0.08
ER/PR negative for both
<1 CTC versus ≥1 CTC 0.76 0.22 2.69 0.69 1.14 0.55 2.39 0.70
<5 CTC versus ≥5 CTC 1.14 0.31 4.14 0.85 1.05 0.28 3.91 0.94
HER-2/neu positive
<1 CTC versus ≥1 CTC 0.64 0.15 2.77 0.58 0.37 0.07 1.97 0.34
<5 CTC versus ≥5 CTC 1.25 0.27 5.71 0.79 0.97 0.18 5.33 0.97
HER-2/neu negative
<1 CTC versus ≥1 CTC 0.62 0.26 1.49 0.29 0.51 0.19 1.37 0.18
<5 CTC versus ≥5 CTC 0.42 0.11 1.59 0.08 0.51 0.13 2.05 0.23
Triple negative
<1 CTC versus ≥1 CTC 0.40 0.11 1.51 0.24 0.31 0.08 1.14 0.11
<5 CTC versus ≥5 CTC 0.56 0.11 2.71 0.39 0.60 0.13 2.82 0.45
High grade
<1 CTC versus ≥1 CTC 0.65 0.28 1.47 0.31 0.42 0.17 1.06 0.09
<5 CTC versus ≥5 CTC 0.56 0.19 1.69 0.22 0.44 0.13 1.46 0.09
Low/intermediate grade
<1 CTC versus ≥1 CTC 0.87 0.15 5.08 0.87 1.34 0.18 9.70 0.76
<5 CTC versus ≥5 CTC 1.44 0.20 10.50 0.74 NAa NAa NAa 0.19
ER, estrogen receptor; NR, not reached; PR, progesterone receptor; NA, not applicable.
aNo events in patients with five or more CTCs.
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not taking statins (44.0% versus 73.8%; P = 0.005); the
proportion of patients with ≥5 CTCs was also lower in
patients taking statins (12.0% versus 36.9%; P = 0.02).
This effect was more striking for patients using H-statins
than for patients using L-statins.
Role of CTCs in Primary IBC
In nonmetastatic breast cancer patients, a cut-off at one
CTC is established based on previous trials [29-31],
therefore, we analyzed the prognostic value of CTCs by
using this cut-off in stage III IBC patients as well.
Among patients with stage III IBC, non-significant
differences occurred in PFS (HR = 0.66; 95% CI, 0.31 to
1.39; P = 0.29) and OS (HR = 0.54; 95% CI, 0.24 to 1.26;
P = 0.48) in patients with no CTCs compared with those
of patients with one or more CTCs (Figure 4). In
exploratory analysis, we evaluated the prognostic
value of CTCs by using a cut-off at 5. Similarly tothese data, patients with fewer than 5 CTCs had a
nonsignificantly better PFS (HR = 0.69; 95% CI, 0.26
to 1.78; P = 0.38) and OS (HR = 0.75; 95% CI, 0.27 to
2.06; P = 0.53) than patients with five or more CTCs.
Of the 77 patients with stage III IBC, 15 (19.2%)
achieved a pathologic complete response (pCR) after
treatment with neoadjuvant chemotherapy; however,
no correlation was found between baseline CTCs count
and pCR. Table 5 shows association between CTCs and
pCR in stage III IBC patients.
Discussion
To our knowledge, this is the first study to assess
the prognostic value of CTCs in patients with newly
diagnosed IBC. This study indicates that baseline
CTCs, as enumerated by the CellSearch technology,
are prognostic for PFS and OS in patients with newly
diagnosed mIBC. The proportion of patients with a
baseline CTC count of ≥1 in stage III and in mIBC
Table 3 Kaplan-Meier progression-free survival (PFS) and overall survival (OS) estimates stratified by CTC level and pa-
tient and tumor characteristics in patients with newly diagnosed metastatic IBC
Progression-free survival Overall survival
Variable Hazard ratio Lower 95% CI Upper 95% CI P value Hazard ratio Lower 95% CI Upper 95% CI P value
All patients
<1 CTC vs. ≥ 1 CTC 0.40 0.21 0.75 0.03 0.29 0.14 0.62 0.03
<5 CTC vs. ≥ 5 CTC 0.76 0.43 1.31 0.30 0.65 0.35 1.19 0.15
ER/PR positive for either
<1 CTC vs. ≥ 1 CTC 0.30 0.13 0.67 0.03 0.14 0.05 0.37 0.02
<5 CTC vs. ≥ 5 CTC 0.57 0.27 1.20 0.13 0.54 0.24 1.22 0.14
ER/PR negative for both
<1 CTC vs. ≥ 1 CTC 0.69 0.24 2.00 0.54 0.64 0.19 2.19 0.54
<5 CTC vs. ≥ 5 CTC 0.97 0.41 2.27 0.94 0.67 0.26 1.73 0.37
HER-2/neu positive
<1 CTC vs. ≥ 1 CTC 0.22 0.05 0.90 0.11 NA a NA a NA a 0.11
<5 CTC vs. ≥ 5 CTC 0.82 0.20 3.32 0.78 0.48 0.10 2.36 0.38
HER-2/neu negative
<1 CTC vs. ≥ 1 CTC 0.75 0.32 1.72 0.53 0.52 0.21 1.29 0.26
<5 CTC vs. ≥ 5 CTC 0.66 0.36 1.22 0.16 0.58 0.30 1.14 0.09
Triple negative
<1 CTC vs. ≥ 1 CTC 0.92 0.22 3.79 0.91 0.79 0.20 3.04 0.74
<5 CTC vs. ≥ 5 CTC 0.34 0.10 1.14 0.01 0.35 0.10 1.28 0.02
High Grade
<1 CTC vs. ≥ 1 CTC 0.38 0.19 0.77 0.03 0.23 0.10 0.54 0.03
<5 CTC vs. ≥ 5 CTC 0.61 0.31 1.18 0.11 0.54 0.26 1.12 0.08
Low/intermediate grade
<1 CTC vs. ≥ 1 CTC 0.75 0.12 4.54 0.77 1.05 0.13 8.45 0.96
<5 CTC vs. ≥ 5 CTC 1.30 0.44 3.87 0.61 0.87 0.28 2.71 0.81
Visceral metastases
<1 CTC vs. ≥ 1 CTC 0.13 0.05 0.32 0.01 0.00 0.00 0.00 0.03
<5 CTC vs. ≥ 5 CTC 0.66 0.30 1.45 0.28 0.49 0.21 1.16 0.07
Non-visceral metastases
<1 CTC vs. ≥ 1 CTC 0.66 0.28 1.56 0.39 0.62 0.22 1.77 0.44
<5 CTC vs. ≥ 5 CTC 0.87 0.40 1.88 0.71 0.78 0.33 1.83 0.55
Bone metastasis
<1 CTC vs. ≥ 1 CTC 0.29 0.13 0.66 0.03 0.18 0.06 0.50 0.06
<5 CTC vs. ≥ 5 CTC 0.67 0.31 1.43 0.28 0.51 0.22 1.20 0.12
No-bone metastasis
<1 CTC vs. ≥ 1 CTC 0.56 0.21 1.51 0.33 0.47 0.16 1.41 0.29
<5 CTC vs. ≥ 5 CTC 0.78 0.34 1.79 0.55 0.78 0.32 1.87 0.56
ER, estrogen receptor; NR, not reached; PR, progesterone receptor; NA, not applicable.
aNo events in patients with fewer than one CTCs.
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higher than the proportions previously reported in
patients with non-IBC, even for those with metastatic
disease. In contrast, the proportion of patients with
five or more CTCs in metastatic IBC was 45.7%,within the range previously observed in patients with
metastatic breast cancer [18-20]. We also confirmed
the findings of previous reports that tumors in patients
with IBC frequently were hormone-receptor negative,
were of high grade, and overexpressed HER2 [7-9,11].
Figure 4 Kaplan-Meier estimates of probabilities of progression-free survival (A, cut-off 1 CTC; C, cut-off 5 CTCs), and overall survival
(B, cut-off 1 CTC; C, cut-off 5 CTCs cut-off 1 CTC; D, cut-off 5 CTCs) according to baseline circulating tumor cell count in patients with
newly diagnosed stage III inflammatory breast cancer.
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CTCs was lower in patients with nonmetastatic IBC
than in those with metastatic IBC (54.5% versus 84.3%;
P = 0.0002). The previously reported prevalence of CTCs
among patients with early primary non-IBC is lower
(range, 21% to 38%) [29,30,32-36] than that of CTCs
among patients with stage III IBC in this study (55.5%).
In a phase II study of HER2-positive primary inflammatory
breast cancer patients, the prevalences of patients with one
or more CTCs and five or more CTCs were 35% and 13%,
respectively, and lower compared with our study, which
includes HER2-negative patients as well [36]; unfortunately,
we are not aware of any data on CTC prevalence in patients
with newly diagnosed locally advanced non-IBC, a more
appropriate group for comparison with our patients with
stage III IBC.In our study, we did not observe a correlation between
pathologic complete remission and patients’ outcome,
and similar to previous reports, we observed a lack of
correlation between baseline CTC count and pathologic
complete remission [32,33,36].
We observed that IBC patients with CTC counts of
less than five had significantly better outcomes than IBC
patients with CTC counts of five or more. In a previous
study of patients with metastatic IBC, we found the
CTC count to be of limited prognostic value; differences
in OS between patients with CTC counts of less than
five and CTC counts of five or more were not significant
[24]. In that study, we observed a lower prevalence of
CTCs and fewer CTCs in patients with metastatic
IBC than in patients with metastatic non-IBC [24].
However, the vast majority of those patients had received
Figure 5 Kaplan-Meier estimates of probabilities of progression-free survival (A, cut-off 1 CTC; C, cut-off 5 CTCs), and overall survival
(B, cut-off 1 CTC; C, cut-off 5 CTCs cut-off 1 CTC; D, cut-off 5 CTCs) according to baseline circulating tumor cell count in patients with
newly diagnosed metastatic IBC.
Table 4 Multivariate analysis
Variable PFS OS
HR (95% CI) P value HR (95% CI) P value
ER/PR status 0.630 0.051 0.468 0.004
Positive for either versus negative for both (0.400 - 1.002) (0.279 - 0.785)
HER2 status 0.309 <0.001 0.268 <0.001
Overexpressed versus negative (0.173 - 0.554) (0.138 - 0.521)
Sites of metastases 1.536 0.143 2.319 0.002
Visceral versus nonvisceral (0.865 - 2.729) (1.364 - 3.942)
Stage 2.939 <0.001 1.681 0.131
mIBC versus stage III (1.818 – 4.750) (0.857 – 3.298)
Baseline CTCs count 1.621 0.044 1.995 0.008
≥5 versus <5 (1.014 - 2.591) (1.202 - 3.309)
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Table 5 Association between baseline CTCs and
pathologic complete remission (pCR) in stage III IBC
non-pCR (%) pCR (%) P value
CTC < 1 30 (85.7) 5 (14.3) 0.39
CTC ≥ 1 32 (76.2) 10 (23.8)
CTC < 5 53 (85.5) 9 (14.5) 0.06
CTC≥ 5 9 (60.0) 6 (40.0)
Mego et al. Breast Cancer Research  (2015) 17:2 Page 11 of 12neoadjuvant or first-line therapy. In our current study,
we observed that CTC counts at the time of disease
progression after chemotherapy were lower than CTC
counts at baseline, and that the proportions of patients
with CTC counts of five or more or with one or more
CTCs were significantly lower at the time of disease
progression than at baseline, which is consistent with
our earlier report [24].
Emerging data suggest that statins, in addition to
their known antiinflammatory effects, might also have
an antiproliferative effect on breast cancer cells; however,
available evidence on breast cancer risk is conflicting
[37,38]. Statins are usually well tolerated, but their adminis-
tration is associated with some important side effects,
including myositis, rhabdomyolysis, hepatotoxicity, and
diarrhea. A recent cohort study showed that use of weakly
lipophilic to hydrophilic statins (H-statins) is associated
with significantly improved PFS compared with no statin
use in patients with IBC [25]. In our study, we observed
that patients who took statins before the diagnosis of IBC
had significantly lower baseline CTC counts than patients
not taking statins. Consistent with previous observations,
patients who used H-statins had lower baseline CTC
counts compared with patients without statins. These
data, even though hypothesis generating, further add
credence to the earlier observation that statins might
have an anticancer effect, especially in IBC, and warrant
additional study.
Conclusion
In conclusion, this retrospective study suggests a prognostic
value of CTCs in patients with newly diagnosed IBC. We
observed that patients with nonmetastatic IBC had a lower
CTC prevalence and lower CTC counts at progression than
did patients with metastatic IBC. Further research should
focus on characterization of CTCs in IBC patients and the
implications for treatment decisions.
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